{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:49:46Z","timestamp":1789145386030,"version":"build-2803163510"},"reference-count":45,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2021,12,2]]},"DOI":"10.1080\/17474086.2021.1970522","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T07:57:04Z","timestamp":1630483024000},"page":"1137-1145","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Belantamab mafodotin for the treatment of relapsed\/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis"],"prefix":"10.1080","volume":"14","author":[{"given":"Andreas","family":"Nikolaou","sequence":"first","affiliation":[{"name":"Modelling and Simulation, Evidera, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva","family":"Ambavane","sequence":"additional","affiliation":[{"name":"Modelling and Simulation, Evidera, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Shah","sequence":"additional","affiliation":[{"name":"Modelling and Simulation, Evidera, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkang","family":"Ma","sequence":"additional","affiliation":[{"name":"Modelling and Simulation, Evidera, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Tosh","sequence":"additional","affiliation":[{"name":"Modelling and Simulation, Evidera, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venediktos","family":"Kapetanakis","sequence":"additional","affiliation":[{"name":"Modelling and Simulation, Evidera, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Willson","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-2395","authenticated-orcid":false,"given":"Cosmina","family":"Hogea","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorsh","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Sapra","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-5585","authenticated-orcid":false,"given":"Yevgeniy","family":"Samyshkin","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Brentford, Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"cit0001","unstructured":"SEER Cancer Statistics. Cancer stat facts: myeloma; 2020 [cited 2020 Feb 27]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0841-y"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402"},{"key":"cit0004","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. Version 4.2021 [Updated December 10,2020; Accessed January 14, 2021]. Available from: http:\/\/www.nccn.org"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0002"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02096"},{"key":"cit0008","unstructured":"Janssen Biotech Inc. DARZALEX (Daratumumab) prescribing information; 2019 [cited 2021 Apr 22]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761036s024lbl.pdf"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"cit0010","unstructured":"ODAC briefing document. FDA. Published February 26, 2019. https:\/\/www.fda.gov\/media\/121669\/download. Cited 2021 Jul 27."},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5207"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.77"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"cit0016","unstructured":"GlaxoSmithKline. BLENREP (Belantamab Mafodotin-blmf) prescribing information [updated 2020;cited 2021 Jan 14]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761036"},{"key":"cit0017","unstructured":"European Medicines Agency. BLENREP 100 mg powder. Summary of product characteristics. 2020 [cited 2021 Apr 22]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/blenrep-epar-product-information_en.pdf."},{"key":"cit0018","unstructured":"European Medicines Agency. Blenrep (belantmab mafodotin); 2020 [cited 2021 Apr 21]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/blenrep-epar-medicine-overview_en.pdf"},{"key":"cit0019","volume-title":"Society of Hematologic Oncology (SOHO) Annual Meeting","author":"Suvannasankha A","year":"2020"},{"key":"cit0020","unstructured":"Institute for Clinical and Economic Review (ICER). Treatment options for relapsed or refractory multiple myeloma: effectiveness, value, and value-based price benchmarks: final evidence report and meeting summary; 2016 [updated 2016 Jun 9; cited 2021 Feb 23]. Available from: http:\/\/icerorg.wpengine.com\/wp-content\/uploads\/2020\/10\/MWCEPAC_MM_Final_Evidence_Report_061016V3.pdf"},{"key":"cit0021","unstructured":"Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011 (last updated Mar 2013)."},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-122"},{"key":"cit0023","unstructured":"Phillippo DM, Ades AE, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016."},{"key":"cit0024","unstructured":"InHealth. Physicians\u2019 fee & coding guide 2019. Commercial fee range - fees on disc. 2019."},{"key":"cit0025","unstructured":"GlaxoSmithKline. Resource use survey: treatment of relapsed\/refractory multiple myeloma in patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody (data on file). 2019."},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.08.010"},{"key":"#cr-split#-cit0027.1","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule look-up tool 2019 [2019 Oct 24"},{"key":"#cr-split#-cit0027.2","unstructured":"Acessed 2019 Oct 24]. Available from: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/search\/search-criteria.aspx."},{"key":"cit0028","unstructured":"Karyopharm Therapeutics Inc. XPOVIO\u2122 (Selinexor) prescribing information: U.S. Food and Drug Administration; [updated 2020; accessed 2021 Jan 14]. Available from: https:\/\/www.karyopharm.com\/wp-content\/uploads\/2019\/07\/NDA-212306-SN-0071-Prescribing-Information-01July2019.pdf."},{"key":"cit0029","unstructured":"IBM. Micromedex\u00ae REDBOOK\u00ae 2019 [Accessed: Oct 2019]. Available from: https:\/\/www.ibm.com\/products\/micromedex-red-book."},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-35"},{"key":"cit0031","volume-title":"62nd ASH Annual Meeting and Exposition","author":"Delforge M","year":"2020"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12454579"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0327-2"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.04.857"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.1.29"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1194278"},{"key":"cit0037","unstructured":"National Institute for Health and Care Excellence. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma: technology appraisal guidance [TA510]. 2018."},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.01.009"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2012.760159"},{"key":"cit0040","first-page":"204","volume":"8","author":"Roy A","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0395-6"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603326"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X06290495"},{"key":"cit0044","unstructured":"HCUPnet. Weighted national estimates from HCUP National Inpatient Sample (NIS), 2016, Agency for Healthcare Research and Quality (AHRQ), based on data collected by individual States and provided to AHRQ by the States. Statistics by Principal Diagnosis and Payer (insurance status). 2016 [Accessed 2020 Oct 7]. Available from: https:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2021.1970522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T14:45:27Z","timestamp":1641998727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2021.1970522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,2]]}},"alternative-id":["10.1080\/17474086.2021.1970522"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2021.1970522","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}